Finance

Lists
NOV:ETR
Novo Nordisk A/S
34,29 €
-0,46%
(-0,16) 1D
13 ოქტ, 17:35:53 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOV...
Open
34,72 €
High
34,77 €
Low
34,22 €
Mkt. cap
128,40 მლრ.
Avg. vol.
180,74 ათ.
Volume
68,97 ათ.
52-wk high
54,87 €
52-wk low
30,24 €
No. of employees
67 ათ.
Open
34,72 €
High
34,77 €
Low
34,22 €
Mkt. cap
128,40 მლრ.
Avg. vol.
180,74 ათ.
Volume
68,97 ათ.
52-wk high
54,87 €
52-wk low
30,24 €
No. of employees
67 ათ.
News stories
From web sources and news partners
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOმაზიარ მაიკ დუსტარ
Employees66,7 ათ.
Founded1923
HeadquartersBagsværd, დედაქალაქის რეგიონი, დანია
SectorPharmaceutical industry
Websitenovonordisk.com
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
6,18 DKK / 5,03 DKK
+22,87%beat
Revenue / Est. (DKK)
78,49 მლრდ. / 71,45 მლრდ.
+9,86%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
74,98 მლრდ.
79,14 მლრდ.
96,82 მლრდ.
78,49 მლრდ.
Cost of goods sold
14,47 მლრდ.
14,17 მლრდ.
13,60 მლრდ.
17,10 მლრდ.
Cost of revenue
14,47 მლრდ.
14,17 მლრდ.
13,60 მლრდ.
17,10 მლრდ.
Research and development expenses
11,49 მლრდ.
12,67 მლრდ.
10,28 მლრდ.
11,46 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15,76 მლრდ.
17,14 მლრდ.
13,22 მლრდ.
16,31 მლრდ.
Operating expense
27,25 მლრდ.
29,73 მლრდ.
23,61 მლრდ.
28,00 მლრდ.
Total operating expenses
41,72 მლრდ.
43,90 მლრდ.
37,20 მლრდ.
45,10 მლრდ.
Operating income
33,25 მლრდ.
35,24 მლრდ.
59,62 მლრდ.
33,39 მლრდ.
Other non operating income
1,53 მლრდ.
-241,00 მლნ.
-
-
EBT including unusual items
25,52 მლრდ.
34,18 მლრდ.
62,17 მლრდ.
26,88 მლრდ.
EBT excluding unusual items
35,09 მლრდ.
37,62 მლრდ.
62,17 მლრდ.
33,20 მლრდ.
Income tax expense
5,51 მლრდ.
7,29 მლრდ.
13,62 მლრდ.
5,89 მლრდ.
Effective tax rate
21,60%
21,34%
21,90%
21,90%
Other operating expenses
-
-81,00 მლნ.
106,00 მლნ.
234,00 მლნ.
Net income
20,01 მლრდ.
26,89 მლრდ.
48,56 მლრდ.
20,99 მლრდ.
Net profit margin
26,68%
33,98%
50,15%
26,74%
Earnings per share
4,50
6,04
6,63
6,18
Interest and investment income
307,00 მლნ.
4,41 მლრდ.
-
1,31 მლრდ.
Interest expense
-
-4,97 მლრდ.
-
-1,50 მლრდ.
Net interest expenses
307,00 მლნ.
-560,00 მლნ.
-
-186,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
36,49 მლრდ.
36,66 მლრდ.
63,13 მლრდ.
36,99 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები